Future research should investigate the feasibility of using ANGPTL3, ANGPTL4, and ANGPTL8 as biomarkers in DR and assess whether ANGPTL3-targeted therapies can improve disease progression in DR while managing dyslipidemia. This evidence concerns the gene ANGPTL4 and metabolic syndrome.